We do not know whether women with serious mental illness in prison access primary care services. We would like to understand more about this. Hardly any evidence exists about how imprisoned women with SMI use primary care services. These services include general practice, dentists, eye health (opticians) and pharmacists. We want to find out how such services meet their healthcare needs and how these experiences are racially differentiated. This Study is led by WRIHW Fellow Prof Tammi Walker.

Professor Tammi Walker, Department of Psychology, Durham University is hosting with TEWV Health & Justice Services on February 18th, 2025, the 1st Girls and Women involved with the Criminal Justice System Conference.

With the global increase in ageing populations, a clear understanding of the physiological and pathological changes associated with ageing is vital for advancing research and clinical practice. Following the World Health Organization’s decision to classify age-related aetiologies, the International Consortium to Classify Ageing-Related Pathologies (ICCARP), including Wolfson Research Institute Fellow, Professor Paul Chazot, was established in 2023.

Enhance your sleep and dreaming experiences with the transformative power of plants. You may already be familiar with the calming effects of chamomile and lavender for a restful night’s sleep, but there’s much more to discover.

Cumbria, Northumberland, Tyne and Wear NHS Foundation Trust (CNTW), a leading provider of mental health and disability services, has partnered with Durham University, Gateshead Council, Northumbria University and community organisation ReCoCo on a project that aims to redefine the role of lived experience in health research.

I joined you in the Wolfson Institute for Health and Wellbeing last week as the Director – I am delighted to have now started in the role!

Researchers, policy makers and politicians from across the North of England have gathered at Durham University to discuss worsening health and work inequalities for women in the region.

Our researchers are changing lives by equipping clinicians and patients with the skills to help manage painful health conditions without using potentially harmful strong opioids.

Key Highlights: Ellorarxine, a novel drug compound developed by Nevrargenics, has demonstrated antioxidant and anti-inflammatory effects, which make it a promising new therapy for treating ALS. The results showed that Ellorarxine increases MAP2 expression at low concentrations, induces neurite outgrowth, ameliorates neuroinflammation and modifies GluA2 expression. The MHRA provided scientific advice for the design of the First in Human study and the non-clinical plan.

Around the world, individuals are living longer, but an increased average lifespan does not always equate to an increased health span. With advancing age, the increased prevalence of ageing-related diseases can have a significant impact on health status, functional capacity and quality of life.

This week, the 15 NIHR Applied Research Collaborations (ARCs) in England celebrate their fifth birthday – marking five years of working together regionally and nationally, to develop and deliver applied health and care research that tackles some of our most pressing needs.

Aging-related decline in memory and synaptic function are associated with the dysregulation of calcium homeostasis, attributed to the overexpression of voltage-gated calcium channels (VGCC).